Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Andros Pharmaceuticals Co's share price is NT$32.30.
Andros Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.12. Hence, Andros Pharmaceuticals Co's PS Ratio for today is 271.43.
The historical rank and industry rank for Andros Pharmaceuticals Co's PS Ratio or its related term are showing as below:
ROCO:6917'
s PS Ratio Range Over the Past 10 Years
Min: 177.08 Med: 825.69 Max: 5610
Current: 271.42
During the past 7 years, Andros Pharmaceuticals Co's highest PS Ratio was 5610.00. The lowest was 177.08. And the median was 825.69.
ROCO:6917's PS Ratio is ranked worse than 91.28% of 929
companies
in the Biotechnology industry
Industry Median: 9.13
vs ROCO:6917: 271.42
During the past 7 years, Andros Pharmaceuticals Co's highest 3-Year average Revenue per Share Growth Rate was 115.40% per year. The lowest was -78.10% per year. And the median was -4.95% per year.
Back to Basics: PS Ratio
Andros Pharmaceuticals Co (ROCO:6917) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Andros Pharmaceuticals Co PS Ratio Related Terms
Andros Pharmaceuticals Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6917 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Andros Pharmaceuticals Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Andros Pharmaceuticals Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Andros Pharmaceuticals Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Andros Pharmaceuticals Co's Share Price of today is NT$32.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Andros Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Andros Pharmaceuticals Co (ROCO:6917) has a PS Ratio of 271.43 as of Jul. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Andros Pharmaceuticals Co and its competitors. This is 67% below median its historical median of 825.69. Over the past decade, Andros Pharmaceuticals Co's PS Ratio has ranged from 177.08 to 5,610.00. According to the industry distribution chart, Andros Pharmaceuticals Co ranks #848 out of 929 companies in the Biotechnology industry, placing it in the top 91.3%.
Is Andros Pharmaceuticals Co's PS Ratio too high?
Andros Pharmaceuticals Co's current PS Ratio of 271.43 is 67% below median its 10-year median of 825.69. Over the past 10 years, this metric has ranged from a low of 177.08 to a high of 5,610.00. The Biotechnology industry median PS Ratio is 9.13. Andros Pharmaceuticals Co's value of 271.43 is 2872.9% above this industry median. Based on the distribution chart, Andros Pharmaceuticals Co ranks #848 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Andros Pharmaceuticals Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Andros Pharmaceuticals Co ranks #848 out of 929 companies for PS Ratio. This places Andros Pharmaceuticals Co in the lower half of its industry. The industry median PS Ratio is 9.13. Andros Pharmaceuticals Co's value of 271.43 is 2872.9% above this benchmark. Historically, Andros Pharmaceuticals Co's own PS Ratio has ranged from 177.08 to 5,610.00 over the past decade. While the company's 10-year median is 825.69 vs. the industry median of 9.13, Andros Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.13, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Andros Pharmaceuticals Co's current PS Ratio of 271.43 is 2872.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Andros Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Andros Pharmaceuticals Co's current PS Ratio is 271.43, which is 67% below median its own 10-year median of 825.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.49, compared to a current price of NT$32.30 — trading 80.5% below its estimated fair value. The current PS Ratio is 271.43, which is 67% below median its 10-year median of 825.69 and 2872.9% above the Biotechnology industry median of 9.13. Andros Pharmaceuticals Co's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current PS Ratio is 271.43 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$32.30 is trading 80.5% below its estimated GF Value™ of NT$165.49.
GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for ROCO:6917:
PS Ratio: 271.43 (67% below median its 10-year median of 825.69)
GF Value™: NT$165.49 vs. price of NT$32.30 (80.5% below fair value)
Industry Position: 2872.9% above the Biotechnology median (#848 of 929)
No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score
Get the complete analysis for ROCO:6917
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6917 has been successfully added to your 
